
AstraZeneca seals manufacturing deal to deliver COVID-19 vaccine in China
pharmafile | August 7, 2020 | News story | Manufacturing and Production, Medical Communications |Â Â AstraZeneca, COVID-19, China, pharmaÂ
AstraZeneca has signed its first deal in China to produce and deliver its vaccine candidate against COVID-19 in the country, partnering up with manufacturing firm Shenzhen Kangtai Biological Products.
The deal is for 100 million doses of the candidate by the end of this year, known as AZD1222, which AZ is working on in partnership with the University of Oxford.
The partnership stipulates that Shenzhen Kangtai must raise its capacity to deliver 200 million by the close of 2021. There are around 1.4 billion citizens in China, and the country is AstraZeneca’s biggest market.
Early data has shown that the candidate has successfully generated immune and T cell responses in patients, and Phase 2/3 trials kicking off back in May. The agreement also leaves the door open for collaboration between the two firms on the delivery of the vaccine to other global markets.
The deal is the latest in a series recently signed by the pharma giant, which includes the promise of 400 million doses to Europe, with the goal of ramping up capacity to deliver one billion doses by September this year.
Matt Fellows
Related Content

AstraZeneca’s Trixeo approved in EU for asthma
AstraZeneca’s Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate) has been approved in the European Union as a …

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …






